Johnson & Johnson(NYSE) JNJ

Johnson & Johnson makes medicine for sick people. They also create tools for doctors to use in surgery. These products help people stay healthy and recover from illness.

Medicines and Medical Tools

• Innovative Medicine: Focuses on drugs for cancer, immune disorders, and brain health; sales were $31.8 billion in the fiscal six months of 2026.
• MedTech: Includes surgical equipment, orthopedic implants, and vision care; sales reached $17.6 billion in the fiscal six months of 2026.
• Oncology: Medicines for cancer treatment such as Darzalex and Carvykti; generated $14.4 billion in sales during the fiscal six months of 2026.
• Immunology: Drugs for autoimmune diseases, which are conditions where the body attacks itself; brought in $7.2 billion in the fiscal six months of 2026.
• Neuroscience: Products for brain health and conditions like major depressive disorder, a form of clinical depression; sales were $4.5 billion in the fiscal six months of 2026.

Moving the Business Forward

• Acquired Intra-Cellular Therapies on April 2, 2025, to add the neuroscience medicine Caplyta to its product portfolio.
• Announced a plan in October 2025 to separate the Orthopaedics business into a standalone entity.
• Introduced new heart procedure technologies including the Varipulse and Trupulse systems in the MedTech segment.
• Launched a supply chain restructuring program in 2026 to exit certain manufacturing locations and streamline operations.

What Makes Them Different

The company maintains a global operational footprint with $27.9 billion in U.S. sales and $21.5 billion in international sales during the fiscal six months of 2026. It dedicated $7.2 billion to research and development during that same period to fuel its pipeline of new treatments.

The Latest Numbers

• Worldwide sales reached $49.4 billion in the fiscal six months of 2026, up 8.2% year over year.
• Operational sales growth, which excludes the impact of changing currency values, was 6.0% for the fiscal six months of 2026.
• Net earnings for the fiscal six months of 2026 were $10.8 billion.
• Cash and marketable securities totaled $20.8 billion as of June 28, 2026.
• Total debt stood at $49.0 billion at the end of the fiscal second quarter of 2026.

Bottom Line

Johnson & Johnson is shifting its focus toward high-margin medicines and medical technology to drive growth. This transformation involves separating its Orthopaedics unit while investing in innovative treatments for cancer and immune diseases.